A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Inclusion Criteria: 1. Age ≥18 years old, both male and female; 2. patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment; 3. Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm; 4. The investigator determines that the patient is amenable to treatment with karelizumab or apatinib; 5. Voluntary enrollment; good compliance and willingness to cooperate with follow-up. Exclusion Criteria: 1. Pregnant or lactating women; 2. Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.); 3. Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.); 4. Patients who, in the judgment of the investigator, are not suitable for inclusion.